Pyxis Oncology Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Pyxis Oncology, Inc. (PYXS) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-77.33-73.79-120.72-75.98-12.83
Depreciation & Amortization2.981.930.710.650.47
Stock Based Compensation12.9516.9515.766.440.04
Change in Working Capital-11.82-14.074.506.681.87
Change in Accounts Payable1.20-3.51-8.334.640.56
Change in Other Working Capital-3.200.6612.832.031.31
Other Operating Activities0.7014.571.136.840.37
Net Cash from Operating Activities-57.67-70.71-89.34-35.33-10.08
Investing Activities
Capital Expenditures-0.24-6.73-6.40-0.54-1.48
Acquisitions0.006.660.00-0.050.00
Purchases of Investments8.39-196.830.00-0.050.00
Sales/Maturities of Investments168.5192.050.000.000.00
Other Investing Activities0.0092.050.000.000.00
Net Cash from Investing Activities8.16-104.85-6.40-0.59-1.48
Financing Activities
Common Stock Issued51.876.120.18152.460.04
Common Stock Repurchased-0.24-0.450.000.000.00
Other Financing Activities7.70-0.450.000.000.00
Net Cash from Financing Activities59.335.930.18304.040.04
Summary
Net Change in Cash9.81-169.63-95.55268.13-11.53
Cash at Beginning of Period11.14180.77276.328.190.00
Cash at End of Period20.9528.00180.77276.320.00
Free Cash Flow-57.91-70.71-95.73-35.87-11.57
Supplemental Disclosures
Interest Paid0.010.000.000.000.00
Income Taxes Paid0.160.050.020.000.00